Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
- Topical (VLU): 0.5 mg/mL or 1.6 mg/mL LL-37 solution applied to wound bed (25 µL/cm²) every third day for 4 weeks.
- Oral (COVID-19): recombinant LL-37 expressed in Lactococcus lactis, dosing per trial protocol.